Top 10 Quoted Investments
Below are the top 10 quoted investments held by the Trust with their contribution to the Trust's Net Asset Value as at 31 March 2023. For links directly to the companies' website, please click the logos.
For a full listing of the Trust's U.S. securities at each quarter end, please refer to the Trust's 13F filing: https://www.sec.gov/cgi-bin/browse-edgar?CIK=942257
Venture Fund Investments
SV Fund VI
5.8% NAV as at 28 February 2023.
An investment in a venture capital fund, SV Fund VI, which invests in unquoted portfolio companies across three sectors: biotechnology, healthcare & IT and medical devices. The Trust made a commitment of $30m to the fund on 19 October 2016, equivalent to 7.5% of the total commitments, which has been drawn down over the investment period.
SV Biotech Crossover Fund ("SV BCOF")
4.2% of NAV as at 28 February 2023.
SV BCOF focuses on later stage and/or pre-IPO opportunities and invests in clinical and near clinical stage biotech companies in the UK, EU and US that have the potential to deliver excellent investor returns and address significant unmet medical needs in patients. The Trust's $30m commitment was only 27% drawn down at 28 February 2023.
Directly-held Unquoted Investments
Below are the directly-held unquoted investments held by the Trust with their contribution to the Trust's Net Asset Value as at 28 February 2023.
Exited with Contingent Milestones
Exited unquoted companies for which the Trust retains rights to receive future contingent performance-based payments are shown below, including their contribution to the Trust's Net Asset Value as at 28 February 2023.
- Ikano Therapeutics 1.4% NAV
- Archemix 0.2% NAV
- Convergence Pharmaceuticals 0.1% NAV
- Nordic Consulting Partners Holdings 0.0% NAV
- Spinal Kinetics 0.0% NAV